Showing 4521-4530 of 5910 results for "".
- RG6501 (OpRegen) Full Phase 1/2a Results to Be Presented at ARVO Annual Meetinghttps://modernod.com/news/rg6501-opregen-full-phase-12a-results-to-be-presented-at-arvo-annual-meeting/2480697/Lineage Cell Therapeutics announced that full results from a phase 1/2a clinical study of RG6501 (OpRegen), a retinal pigment epithelium cell transplant therapy currently in development for the treatment of dry age-related macular degeneration (AMD), will be presented at the 2022 Associ
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- SECO International and National Academy of Opticianry Expand Partnership to Bring Optician-Focused Education to SECO 2023https://modernod.com/news/seco-international-and-national-academy-of-opticianry-expand-partnership-to-bring-optician-focused-education-to-seco-2023/2480695/SECO International announced that it has expanded a partnership with the National Academy of Opticianry (NAO) to bring a dedicated educational track for opticians to SECO 2023. The NAO, founded in 1963, represents opticians worldwide and is dedicated solely to education and training of all o
- Bunkers That Save Sight? UConn Researchers Take a Close Lookhttps://modernod.com/news/bunkers-that-save-sight-uconn-researchers-take-a-close-look/2480693/Chronically stressing the retina can weaken it and damage our ability to see. But retinal cells have a remarkable ability to wall off damage, a team of neuroscientists led by UConn Health reports in the 1 March issue of PNAS. The w
- SECO Announces Its 2022 Award Winnershttps://modernod.com/news/seco-announces-its-2022-award-winners/2480691/SECO International announced the recipients of its 2022 awards. The awards recognize leaders in optometry and their significant contributions to the profession. “It is an honor and privilege to recognize this outstanding group of leaders and their contribution to the pr
- NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trialhttps://modernod.com/news/novasight-announces-successful-results-of-pivotal-amblyopia-treatment-trial/2480689/NovaSight announced positive pivotal data from its multicenter, randomized, controlled trial of CureSight, an eye-tracking based, digital treatment device for amblyopia (lazy eye). The study, which randomized 103 participants aged 4 to 9, compared the improvement in visual outcomes achieved
- Théa Completes its Acquisition of Akorn’s Branded Ophthalmic Productshttps://modernod.com/news/thea-completes-its-acquisition-of-akorns-branded-ophthalmic-products/2480688/Théa Pharma announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn. The transaction expands Théa’s eye care portfolio in the United States. Financial terms of the deal were not disclosed. &
- DORC Launches Eva Nexushttps://modernod.com/news/dorc-launches-eva-nexus/2480687/DORC International announced the launch of Eva Nexus, a device designed to improve efficiency and control in retina, cataract and combined surgery. Eva Nexus introduces multiple innovations in surgical performance and efficiency, including SmartIOP that combines with the existing E
- Lighthouse Guild Opens Technology Center for People Who are Blind or Visually Impairedhttps://modernod.com/news/lighthouse-guild-opens-technology-center-for-people-who-are-blind-or-visually-impaired/2480685/Lighthouse Guild Technology Center, which offers people who are blind or visually impaired access to the latest assistive devices and state-of-the-art technology, celebrated its official opening. The Center occupies 11,000 square feet at Lighthouse Guild’s New York City headquarters and is
- Oculis Announces Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma from Accure Therapeuticshttps://modernod.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. Under the terms of the agreement, Accure